In addition to our own, proprietary pipeline of ADC candidates, we have a number of partnerships and collaborations in place that leverage our technology – and those of our collaborators – to address unmet medical needs. We continually seek innovative partnerships with the goal of advancing science, gaining access to complimentary capabilities, strengthening our financial position, and creating more value for ImmunoGen.
Examples of our partnerships include a strategic cross-licensing agreement with CytomX Therapeutics to develop ProbodyTM drug conjugate (PDC) therapies, a co-development and co-promotion collaboration with MacroGenics to develop a first-in-class ADAM9-targeting ADC, and a strategic collaboration and option agreement with Jazz Pharmaceuticals to develop and commercialize hematology-related ADCs.
Our technology platform has been the basis for a number of high-value partnerships for the company, including the first-ever ADC approved as a treatment option for HER2-positive breast cancer, which is marketed by Roche, called Kadcyla®.
In addition to Roche, we have ADC technology deals in place with Amgen, Bayer, Biotest, Sanofi, and Takeda.